Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 185

  • 3 924 clinical trials
  • 1 545 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 924 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 924 clinical trials

Oropharyngeal squamous cell carcinoma

Not recruiting

Study on Reducing Treatment Intensity for Patients with HPV-Positive Oropharyngeal Cancer Using Cisplatin and Carboplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Cardiff University

Colon cancer

Not recruiting

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Levoleucovorin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Primary mediastinal large B-cell lymphoma

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Universitaet Muenster

Neuroendocrine carcinoma of the skin

Not recruiting

Study of Retifanlimab Combined with Carboplatin, Cisplatin and Etoposide Before Surgery in Patients with Resectable Merkel Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Fondazione GONO G.I.

Soft tissue sarcoma

Not recruiting

Study of Cirtuvivint for Patients with Advanced Soft-Tissue Sarcomas as a Second-Line Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cirtuvivint
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Soft tissue sarcoma

Not recruiting

Study of PM14 Alone and with Radiotherapy for Patients with Advanced Soft Tissue Sarcomas and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Asoc Grupo Espanol De Investigacion En Sarcomas

Hormone-refractory prostate cancer+2

Not recruiting

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Adenocarcinoma pancreas

Not recruiting

Study on Survival in Patients with Resectable Pancreatic Cancer Using Irinotecan, Fluorouracil, Calcium Folinate, and Oxaliplatin Combination Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:La Fundacion Para La Gestion De La Investigacion Biomedica De Cadiz

Colorectal cancer metastatic+2

Not recruiting

Study on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AIO-Studien gGmbH

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Heidelberg University

Uveal melanoma

Not recruiting

Study on the Effects of Sitravatinib and Tislelizumab for Patients with Metastatic Uveal Melanoma and Liver Metastases

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Grupo Espanol Multidisciplinar De Melanoma

Acute lymphocytic leukaemia

Not recruiting

Study of CARCIK-CD19 Cells for Patients with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Fondazione Tettamanti

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Infliximab65 clinical trialsVincristine Sulfate55 clinical trialsAbemaciclib45 clinical trialsIbrutinib43 clinical trialsTrifluridine31 clinical trialsAvelumab30 clinical trialsApalutamide27 clinical trialsAmivantamab25 clinical trialsZanubrutinib24 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.